Head-to-head · Value Score
Gimme Care vs Enhance MD
Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, Enhance MD a 85. Here's who gives you the honest lower price — and where each one bites back.
Gimme Care
#3 · Grade A · Best Value
Est. first month
$130/mo
Save ~90% vs brand-nameEnhance MD
#20 · Grade A- · Great Deal
Est. first month
$169/mo
Save ~87% vs brand-nameThe verdict
Gimme Care takes it on Value Score, 91 to 85 — an est. $130/mo first month, with no teaser step-up baked in. Enhance MD isn't out of it: Shoppers who want a clearly published tiered price with real provider oversight and lab testing, and don't mind a higher entry price for it.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Gimme Care | Enhance MD |
|---|---|---|
| Value Score | 91 (A) | 85 (A-) |
| Est. first month | $130/mo | $169/mo |
| Save vs brand-name | ~90% | ~87% |
| Semaglutide | $130/mo | $212/mo |
| Tirzepatide | $163/mo | $280/mo |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Not publicly listed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Gimme Care
Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.
Why it's a deal
- Low flat price on both molecules ($130 sema / $163 tirz)
- LegitScript-certified pharmacy
- Available in all 50 states
The fine print
- No brand-name option — compounded only
- No oral/sublingual form
Enhance MD
A transparent, dose-flat compounded menu (microdose to sema+tirz combo) with 6-month lab testing and NAD+ on the side — priced higher at entry, with a first-month sema teaser to read past.
Why it's a deal
- Transparent, dose-flat tiered pricing published up front (microdose, sema, tirz, combo)
- Includes 6-month lab testing and provider-led care rather than a bare prescription
- NAD+ and adjacent longevity support available on the same platform
The fine print
- Compounded only — not FDA-approved, and no brand-name or oral/sublingual route
- Semaglutide's $112 first month steps up to $212 — a teaser to plan around
- Higher entry price than the rock-bottom flat-fee programs
- States served are not publicly listed — confirm coverage before you sign up
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.